Health

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 16:00 ET  | Source: Vor Biopharma CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:…

12 months ago

New APOE4 App Uses AI Digital Twins to Help 25% of Population at High Alzheimer’s Risk

Phoenix platform matches users with genetically similar people to predict which interventions actually work. SINGAPORE, July 18, 2025 (GLOBE NEWSWIRE)…

12 months ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 18, 2025 17:15 ET  | Source: Iovance Biotherapeutics, Inc. SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance…

12 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 16:30 ET  | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical…

12 months ago

EURneffy approved as the first needle-free anaphylaxis treatment of adults and children in the UK

Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has…

12 months ago

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on…

12 months ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment for people suffering from DPNP July 18, 2025…

12 months ago

MYOS PET and Leading Veterinarian Urge Action as Weather Extremes Impact Senior Pet Muscle Health

CEDAR KNOLLS, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- With climate changes becoming more severe, veterinary sports medicine and rehabilitation…

12 months ago

EssilorLuxottica: Second-Quarter and First-Half 2025 Results Conference Call Invitation

Second-Quarter and First-Half 2025 ResultsConference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer,Mr PAUL DU SAILLANT, Deputy Chief…

12 months ago

Oncotelic Therapeutics Highlights PeerReviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS,…

12 months ago